ResApp to develop COVID-19 mass screening tool as adjunct to RATs and PCR

ASX-listed respiratory app technology developer ResApp is in the early stages of planning a randomised control trial of its new app-based diagnostic screening tool for COVID-19, following early results showing it had high sensitivity and good specificity.

The early clinical results showed it has potential use as a mass screening test prior to rapid antigen or polymerase chain reaction testing to rule out COVID-19.

Posted in Australian eHealth

Tags: ResApp Health

You need to log in to post comments. If you don't have a Pulse+IT website account, click here to subscribe.

Sign up for Pulse+IT eNewsletters

Sign up for Pulse+IT website access

For more information, click here.

Copyright © 2022 Pulse+IT Communications Pty Ltd
No content published on this website can be reproduced by any person for any reason without the prior written permission of the publisher.
Supported by Social Media Agency | pepperit